Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 6/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.46 |
| ▸ | KDM1A | O60341 | 8/20 | 0.42 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.42 |
| ▸ | PDE4A | P27815 | 3/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4580535 | 0.77 | FGFR4 (0.39) | — | |
| SCHEMBL4580915 | 0.76 | EGLN2 (0.48) | CYP11B1CYP11B2KDM1AEGLN2 | |
| SCHEMBL14177815 | 0.68 | RORC (0.34) | CYP11B2 | |
| SCHEMBL22035592 | 0.65 | KDM1A (0.63) | CYP11B1CYP11B2KDM1A | |
| SCHEMBL4725235 | 0.65 | KDM1A (0.42) | CYP11B1CYP11B2KDM1AEGLN2PDE4A | |
| SCHEMBL4578838 | 0.64 | CYP11B1 (0.46) | CYP11B1CYP11B2KDM1AEGLN2 | |
| SCHEMBL18297999 | 0.64 | CYP11B2 (0.67) | CYP11B1CYP11B2 | |
| SCHEMBL4580083 | 0.63 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL9612021 | 0.62 | CYP11B2 (0.68) | CYP11B1CYP11B2 | |
| SCHEMBL12012339 | 0.62 | CYP11B1 (0.66) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | claimed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | MKI67, CCNB1, RB1 | CYP11B1 380/4885CYP11B2 572/4885KDM1A 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.